Humana (0J6Z) Share Forecast & Price Target

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0J6Z Analyst Ratings

Moderate Buy

12 Buy

5 Hold

0 Sell

Based on 17 analysts giving stock ratings to

Humana

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0J6Z Stock 12 Month Forecast

Average Price Target

$473.38

▲(19.90% Upside)

Based on 17 Wall Street analysts offering 12 month price targets for Humana in the last 3 months. The average price target is $473.38 with a high forecast of $596.00 and a low forecast of $370.00. The average price target represents a 19.90% change from the last price of $394.82.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"175":"$175","386":"$386","597":"$597","280.5":"$280.5","491.5":"$491.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":596,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$596.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":473.375,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$473.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":370,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$370.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[175,280.5,386,491.5,597],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,377.264,394.08984615384617,410.9156923076923,427.7415384615385,444.56738461538464,461.3932307692308,478.21907692307695,495.04492307692306,511.87076923076927,528.6966153846154,545.5224615384616,562.3483076923077,579.1741538461538,{"y":596,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,377.264,384.65715384615385,392.0503076923077,399.4434615384615,406.8366153846154,414.22976923076925,421.6229230769231,429.0160769230769,436.40923076923076,443.80238461538465,451.1955384615385,458.5886923076923,465.98184615384616,{"y":473.375,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,377.264,376.70523076923075,376.14646153846155,375.5876923076923,375.0289230769231,374.47015384615383,373.91138461538463,373.3526153846154,372.7938461538462,372.2350769230769,371.6763076923077,371.11753846153846,370.55876923076926,{"y":370,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":243.659,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":275.175,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":242.706,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":256.172,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":186.91,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":183.305,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":176.36,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":236.143,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":320.968,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":408.128,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":365.309,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":389.847,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":377.264,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$596.00

Average Price Target$473.38

Lowest Price Target$370.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Jason Cassorla

Guggenheim

$471

Buy

19.29%

Upside

Reiterated

10/20/26

Analysts Are Bullish on Top Healthcare Stocks: Abivax SA Sponsored ADR (ABVX), Humana (HUM)

Andrew Mok CFA

Barclays

$582

Buy

47.41%

Upside

Reiterated

10/14/26

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (NASDAQ: BMRN) and Humana (NYSE: HUM)

Ann Hynes

Mizuho Securities

$468→$495

Buy

25.37%

Upside

Reiterated

10/13/26

Humana price target raised to $495 from $468 at MizuhoHumana price target raised to $495 from $468 at Mizuho

Elizabeth Anderson CFA

Evercore ISI

$480

Buy

21.57%

Upside

Reiterated

10/13/26

Evercore ISI Keeps Their Buy Rating on Humana (HUM)

David S Macdonald

Truist Financial

$415→$475

Hold

20.31%

Upside

Reiterated

10/12/26

Humana price target raised to $475 from $415 at TruistHumana price target raised to $475 from $415 at Truist

A.J. Rice

UBS

$405→$495

Hold

25.37%

Upside

Assigned

10/12/26

Analysts Conflicted on These Healthcare Names: Roche Holding AG (Other OTC: RHHVF), Humana (NYSE: HUM) and Arrowhead Pharmaceuticals (NASDAQ: ARWR)

Parker Snure

Raymond James

$520

Buy

31.71%

Upside

Upgraded

10/12/26

Humana upgraded to Outperform from Market Perform at Raymond JamesHumana upgraded to Outperform from Market Perform at Raymond James

Michael Wiederhorn

Oppenheimer

$405→$475

Buy

20.31%

Upside

Reiterated

10/09/26

Oppenheimer Sticks to Its Buy Rating for Humana (HUM)

Michael Ha

Robert W. Baird

$390→$596

Buy

50.95%

Upside

Upgraded

10/09/26

Humana upgraded to Outperform from Neutral at BairdHumana upgraded to Outperform from Neutral at Baird

Ben Hendrix

RBC Capital

$415

Hold

5.11%

Upside

Reiterated

10/07/26

RBC Capital Sticks to Its Hold Rating for Humana (HUM)

Sarah James

Cantor Fitzgerald

$460

Buy

16.51%

Upside

Upgraded

10/07/26

Humana upgraded to Overweight from Neutral at Cantor FitzgeraldHumana upgraded to Overweight from Neutral at Cantor Fitzgerald

Lance Wilkes

Bernstein

$425

Buy

7.64%

Upside

Reiterated

10/05/26

Analysts Are Bullish on These Healthcare Stocks: Humana (HUM), Illumina (ILMN)

David Windley

Jefferies

$624→$420

Buy

6.38%

Upside

Reiterated

09/30/26

Jefferies Remains a Buy on Humana (HUM)

Stephen Baxter

Wells Fargo

$502

Buy

27.15%

Upside

Reiterated

09/15/26

Analysts Are Bullish on Top NA Stocks: Kestra Medical Technologies Ltd. (KMTS), Humana (HUM)

Kevin Fischbeck

Bank of America Securities

―

Buy

―

Assigned

09/08/26

Analysts Are Bullish on These NA Stocks: Securitize (SECZ), Humana (HUM)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Jason Cassorla

Guggenheim

$471

Buy

19.29%

Upside

Reiterated

10/20/26

Analysts Are Bullish on Top Healthcare Stocks: Abivax SA Sponsored ADR (ABVX), Humana (HUM)

Andrew Mok CFA

Barclays

$582

Buy

47.41%

Upside

Reiterated

10/14/26

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (NASDAQ: BMRN) and Humana (NYSE: HUM)

Ann Hynes

Mizuho Securities

$468→$495

Buy

25.37%

Upside

Reiterated

10/13/26

Humana price target raised to $495 from $468 at MizuhoHumana price target raised to $495 from $468 at Mizuho

Elizabeth Anderson CFA

Evercore ISI

$480

Buy

21.57%

Upside

Reiterated

10/13/26

Evercore ISI Keeps Their Buy Rating on Humana (HUM)

David S Macdonald

Truist Financial

$415→$475

Hold

20.31%

Upside

Reiterated

10/12/26

Humana price target raised to $475 from $415 at TruistHumana price target raised to $475 from $415 at Truist

A.J. Rice

UBS

$405→$495

Hold

25.37%

Upside

Assigned

10/12/26

Analysts Conflicted on These Healthcare Names: Roche Holding AG (Other OTC: RHHVF), Humana (NYSE: HUM) and Arrowhead Pharmaceuticals (NASDAQ: ARWR)

Parker Snure

Raymond James

$520

Buy

31.71%

Upside

Upgraded

10/12/26

Humana upgraded to Outperform from Market Perform at Raymond JamesHumana upgraded to Outperform from Market Perform at Raymond James

Michael Wiederhorn

Oppenheimer

$405→$475

Buy

20.31%

Upside

Reiterated

10/09/26

Oppenheimer Sticks to Its Buy Rating for Humana (HUM)

Michael Ha

Robert W. Baird

$390→$596

Buy

50.95%

Upside

Upgraded

10/09/26

Humana upgraded to Outperform from Neutral at BairdHumana upgraded to Outperform from Neutral at Baird

Ben Hendrix

RBC Capital

$415

Hold

5.11%

Upside

Reiterated

10/07/26

RBC Capital Sticks to Its Hold Rating for Humana (HUM)

Sarah James

Cantor Fitzgerald

$460

Buy

16.51%

Upside

Upgraded

10/07/26

Humana upgraded to Overweight from Neutral at Cantor FitzgeraldHumana upgraded to Overweight from Neutral at Cantor Fitzgerald

Lance Wilkes

Bernstein

$425

Buy

7.64%

Upside

Reiterated

10/05/26

Analysts Are Bullish on These Healthcare Stocks: Humana (HUM), Illumina (ILMN)

David Windley

Jefferies

$624→$420

Buy

6.38%

Upside

Reiterated

09/30/26

Jefferies Remains a Buy on Humana (HUM)

Stephen Baxter

Wells Fargo

$502

Buy

27.15%

Upside

Reiterated

09/15/26

Analysts Are Bullish on Top NA Stocks: Kestra Medical Technologies Ltd. (KMTS), Humana (HUM)

Kevin Fischbeck

Bank of America Securities

―

Buy

―

Assigned

09/08/26

Analysts Are Bullish on These NA Stocks: Securitize (SECZ), Humana (HUM)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AMRXAmneal Pharmaceuticals

DNTHDianthus Therapeutics

REPLReplimune Group

VSTMVerastem

OVIDOvid Therapeutics

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Humana

3 Months

Lance WilkesBernstein

Success Rate

13/17 ratings generated profit

Average Return

+19.58%

Copying Lance Wilkes's trades and holding each position for 3 Months would result in 76.47% of your transactions generating a profit, with an average return of +19.58% per trade.

1 Year

Lance WilkesBernstein

Success Rate

13/17 ratings generated profit

Average Return

+34.81%

Copying Lance Wilkes's trades and holding each position for 1 Year would result in 76.47% of your transactions generating a profit, with an average return of +34.81% per trade.

2 Years

Lance WilkesBernstein

Success Rate

17/17 ratings generated profit

Average Return

+58.24%

Copying Lance Wilkes's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +58.24% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0J6Z Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0J6Z has received 19 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. 0J6Z average Analyst price target in the past 3 months is 473.38.

Each month's total comprises the sum of three months' worth of ratings.

0J6Z Financial Forecast

0J6Z Earnings Forecast

Next quarter’s earnings estimate for 0J6Z is -$1.00 with a range of -$1.16 to -$0.60. The previous quarter’s EPS was $7.61. 0J6Z beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0J6Z has Performed in-line its overall industry.

0J6Z Sales Forecast

Next quarter’s sales forecast for 0J6Z is $40.87B with a range of $40.43B to $41.44B. The previous quarter’s sales results were $40.87B. 0J6Z beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0J6Z has Performed in-line its overall industry.

0J6Z Stock Forecast FAQ

What is GB:0J6Z’s average 12-month price target, according to analysts?

Based on analyst ratings, Humana Inc’s 12-month average price target is 473.38.

What is GB:0J6Z’s upside potential, based on the analysts’ average price target?

Humana Inc has 19.90% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Humana Inc a Buy, Sell or Hold?

Humana Inc has a consensus rating of Moderate Buy, which is based on 12 buy ratings, 5 hold ratings and 0 sell ratings.

What is Humana Inc’s share price target?

The average share price target for Humana Inc is 473.38. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $596.00 ,and the lowest forecast is $370.00. The average share price target represents 19.90% Increase from the current price of $394.82.

What do analysts say about Humana Inc?

Humana Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 17 Wall Streets Analysts.

How can I buy shares of Humana Inc?

To buy shares of GB:0J6Z, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Humana (0J6Z) Share Forecast & Price Target

0J6Z Analyst Ratings

0J6Z Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Humana

0J6Z Analyst Recommendation Trends

0J6Z Financial Forecast

0J6Z Earnings Forecast

0J6Z Sales Forecast

0J6Z Stock Forecast FAQ

Detailed List of Analyst Forecasts